

PRESS RELEASE

Published: 06-09-2019

Inhalation Sciences changes CEO

Inhalation Sciences (ISAB), which develops and commercializes world-leading instruments for inhalation research, today announces that it intends to replace its CEO. The company intends to announce the name of its new CEO next week. For the present Lena Heffler will continue as the company's CEO.

Inhalation Sciences (ISAB) develops an advanced aerosol R&D system that minimizes errors, reduces risk and speeds up the development of inhalable drugs. The company is in the early commercialization phase, and has recently announced its intention to validate the technology to meet growing market demand for its use in clinical as well as preclinical trials. This project will continue as planned, as previously communicated, managed by the newly appointed CEO. Marketing and sales of the instrument for pre-clinical use will continue according to plan.

Lena Heffler has asked for leave from her position as CEO on her own initiative, and the Company has already entered into negotiations with her intended successor. The Company intends to announce the name of a new CEO during the coming week. Lena Heffler will remain as the company's CEO for the time being. Following the appointment of the new CEO, she will remain in the Company through her six-month period of notice, focusing on her core key areas of expertise: marketing, sales and project management.

For more information on Inhalation Sciences, please contact:

Fredrik Sjövall, Chairman of the Board E-mail: fredrik.sjovall@inhalation.se

Mobile: +46 (0)70 64 508 75

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments for research into inhalation. The company's patented lab instrument, PreciseInhale®, enables researchers to characterize, with high precision, how aerosols and small particles impact our lungs, and so our health, when we breathe them in.

The information above was provided by Inhalation Sciences Sweden AB (publ) according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on September 6, 2019